PHOSPHODIESTERASE TYPE 5 INHIBITORS IN THE TREATMENT OF ERECTILE DYSFUNCTION: PAST, PRESENT AND FUTURE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This review article describes the differences in efficacy and side effects between available phosphodiesterase type 5 (PDE-5) inhibitors used for treating erectile dysfunction. The most studied PDE-5 inhibitor is sildenafil.

Full Text

Restricted Access

About the authors

S. I Gamidov

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: s_gamidov@oparina4.ru
Dr.Med.Sci., Head of the Department of Andrology and Urology

R. I Ovchinnikov

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: r_ovchinnikov@oparina4.ru
PhD, Head of the Department of Andrology and Urology for Clinic

A. Yu Popova

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: a_popova@oparina4.ru
PhD, SR at the Department of Andrology and Urology

S. Kh Izhbaev

V.I. Kulakov Research Center for Obstetrics, Gynecology and Perinatology of Minzdrav of Russia

Email: s_izhbaev@oparina4.ru
Urologist-Andrologist at the Department of Andrology and Urology

References

  1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence.JAMA. 1993;270:83-90.
  2. Feldman H.A., Goldstein I., Hatzjchristou D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61.
  3. Jackson G., Gillies H., Osterloh I. Past, present, and future: a 7-year update of Viagra (sildenafil citrate). Int J Clin Pract 2005;59:680-91.
  4. Polinski J.M., Kesselheim A.S. Where cost, medical necessity, and morality meet: should US government insurance programs pay for erectile dysfunction drugs? Clin Pharmacol Ther. 2011;89:17-19.
  5. Melman A , Gingell J.C. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999;161:5-11.
  6. Burnett A.L. Nitric oxide in the penis: physiology and pathology. J Urol. 1997;157:320-24.
  7. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol. 1997;79:958-963.
  8. Kotera J., Mochida H., Inoue H., Noto T., Fujishige K., Sasaki T., Kobayashi T., Kojima K., Yee S., Yamada Y., Kikkawa K., Omori K. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction. J Urol. 2012;188:668-674.
  9. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res. 1996;8:47-52.
  10. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med. 1998;338:1397-1404.
  11. Boulton A.J., Selam J.L., Sweeney M., Ziegler D. Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. Diabetologia. 2001;44:1296-1301.
  12. Meuleman E., Cuzin B., Opsomer R.J., Hartmann U., Bailey M.J., Maytom M.C., Smith M.D., Osterloh I.H. A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. BJU Int. 2001;87:75-81.
  13. McCullough A.R., Barada J.H., Fawzy A., Guay A.T., Hatzichristou D. Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. Urology. 2002;60:28-38.
  14. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral Sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N EngI J Med. 1998;338: 1397-1404.
  15. Камалов А.А., Осмоловский Б.Е., Охоботов Д.А., Ходырева Л.А., Тахирзаде Т.Б., Тахирзаде А.М., Геворкян А.Р. Комбинированное лечение больных с эректильной дисфункцией, страдающих расстройствами мочеиспускания, Урология. 2013;3:29-33
  16. Giuliano F., Jackson G., Montorsi F., Martin-Morales A., Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebocontrolled trials and the postmarketing safety database. Int J Clin Pract. 2010;64(2):240-255.
  17. Инструкция по медицинскому применению Динамико.
  18. Klotz T., Sachse R., Heidrich A., Jockenhövel F., Rohde G., Wensing G., Horstmann R., Engelmann R. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol. 2001;19:32-39.
  19. Hellstrom W.J., Gittelman M., Karlin G., Segerson T., Thibonnier M., Taylor T., Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, doubleblind, placebo-controlled trial. J Androl. 2002;23:763-771.
  20. Porst H., Rosen R., Padma-Nathan H., Goldstein I., Giuliano F., Ulbrich E., Bandel T. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13:192-199.
  21. Zumbé J., Porst H., Sommer F., Grohmann W., Beneke M., Ulbrich E. Comparable efficacy of once-daily versus on-demand vardenafil in men with mild-to-moderate erectile dysfunction: findings of the RESTORE study. Eur Urol. 2008;54:204-210.
  22. Rubio-Aurioles E., Porst H., Kim E.D., Montorsi F., Hackett G., Morales A.M., Stuckey B., Büttner H., West T.M., Huynh N.N., Lenero E., Burns P., Kopernicky V. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med. 2012;9:1418-1429.
  23. Padma-Nathan H., McMurray J.G., Pullman W.E., Whitaker J.S., Saoud J.B., Ferguson K.M., Rosen R.C. On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res. 2001;13:2-9.
  24. Brock G.B., McMahon C.G., Chen K.K., Costigan T., Shen W., Watkins V., Anglin G., Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332-1336.
  25. Goldfischer E.R., Kim E.D., Seftel A.D., Baygani S.K., Burns P.R. Impact of low testosterone on response to treatment with tadalafil 5 mg once daily for erectile dysfunction. Urology. 2014;83:1326-1333.
  26. Porst H., Oelke M., Goldfischer E.R., Cox D., Watts S., Dey D., Viktrup L. Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology. 2013;82:667-673.
  27. Buvat J., Hatzichristou D., Boess F.G., Büttner H., Gehchan N., Henneges C., Porst H. Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the ED ATE study. Int J Clin Pract. 2014; 68:1087-99.
  28. Montague D.K., Jarow J.P., Broderick G.A., Dmochowski R.R., Heaton J.P., Lue T.F., Milbank A.J., Nehra A., Sharlip I.D.; Erectile Dysfunction Guideline Update Panel. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174:230-39.
  29. Hatzimouratidis K., Amar E., Eardley I., Giuliano F., Hatzichristou D., Montorsi F., Vardi Y., Wespes E.; European Association of Urology. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol. 2010;57:804-814.
  30. Bai W.J., Li H.J., Dai Y.T., Huang Y.R., Liu J.H., Sorsaburu S., Ji C., Jin J.J., Wang X.F. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy. Asian J Androl. 2015;17:61-67.
  31. Shabsigh R., Seftel A.D., Rosen R.C., Porst H., Ahuja S., Deeley M.C., Garcia C.S., Giuliano F. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006;68:689-696.
  32. Tsertsvadze A., Fink H.A., Yazdi F., MacDonald R., Bella A.J., Ansari M.T., Garritty C., Soares-Weiser K., Daniel R., Sampson M., Fox S., Moher D., Wilt T.J. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med. 2009;151:650-61.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies